Engineered enzymes and uses thereof
The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for research, nutritional care, personal care and industrial purposes.
1. A recombinant engineered enzyme with catalytic activity of defined specificity, characterized by a combination of the following components:
(a) a protein scaffold capable of catalyzing at least one protein cleavage reaction on at least one target substrate and being a serine protease of the structural class S1, and
(b) one or more specificity determining regions (SDRs), wherein the SDRs are peptide sequences inserted into the protein scaffold at one or more positions that correspond structurally or by amino acid sequence homology to the regions 38-48 and 122-130 in human trypsin I having the amino acid sequence shown in SEQ ID NO:1, wherein the inserted SDRs enable the resulting engineered protein to discriminate between at least one target substrate and one or more different substrates.
2. The recombinant engineered enzyme of claim 1 , wherein the SDRs (b) have a length of less than 50 amino acid residues.
3. The recombinant engineered enzyme of claim 2 , wherein the SDRs (b) have a length between two and 20 amino acid residues.
4. The recombinant engineered enzyme of claim 3 , wherein the SDRs (b) have a length between two and ten amino acid residues.
5. The recombinant engineered enzyme of claim 4 , wherein the SDRs (b) have a length between three and eight amino acid residues.
6. The recombinant engineered enzyme of claim 2 , wherein the number of SDRs is at least one.
7. The recombinant engineered enzyme of claim 6 , wherein the number of SDRs is more than one.
8. The recombinant engineered enzyme of claim 6 , wherein the number of SDRs is between two and eleven.
9. The recombinant engineered enzyme of claim 6 , wherein the number of SDRs is between two and six.
10. The recombinant engineered enzyme of claim 1 , wherein the protein scaffold (a) is encoded by a gene of viral origin.
11. The recombinant engineered enzyme of claim 1 , wherein the protein scaffold (a) is encoded by a gene of prokaryotic origin.
12. The recombinant engineered enzyme of claim 1 , wherein the protein scaffold (a) is encoded by a gene of eukaryotic origin.
13. The recombinant engineered enzyme of claim 1 , wherein the protein scaffold (a) is comprised of one or more polypeptides derived from the same or different native enzymes.
14. The recombinant engineered enzyme of claim 1 , wherein the protein scaffold (a) is comprised of one or more polypeptides derived from the same or different native mammalian enzymes.
15. The recombinant engineered enzyme of claim 14 , wherein the mammalian enzymes are human enzymes.
16. A fusion protein comprised of at least one recombinant engineered enzyme of claim 1 and at least one further proteinacious component.
17. The fusion protein of claim 16 , wherein the further proteinacious component is selected from the group consisting of binding domains and fragments thereof.
18. A fusion protein comprised of at least one recombinant engineered enzyme of claim 1 and at least one further functional component.
19. The fusion protein of claim 18 , wherein the functional component is selected from the group consisting of polyethylenglycols, and fragments or derivatives thereof.
20. A composition comprising one or more recombinant engineered enzymes of claim 1 .
21. A composition comprising the fusion protein of claim 18 .
22. A composition comprising the fusion protein of claim 19 .
23. The composition of claim 20 , which is a research composition.
24. The composition of claim 21 , which is a research composition.
25. The composition of claim 22 , which is a research composition.
26. The composition of claim 20 , which further comprises a pharmceutically acceptable carrier(s).
27. The composition of claim 21 , which further comprises a pharmaceutically acceptable carrier(s).
28. The composition of claim 22 , which further comprises a pharmaceutically acceptable carrier(s).
29. The recombinant engineered enzyme of claim 1 , wherein the SDRs are located at one or more positions selected from the group of positions that correspond structurally or by amino acid sequence homology to the regions 41-45 and 125-128 in human trypsin I having the amino acid sequence shown in SEQ ID NO:1.